Current Situation and Challenges in Vitreous Substitutes.
- Published in:
- Macromolecular Bioscience, 2021, v. 21, n. 8, p. 1, doi. 10.1002/mabi.202100066
- By:
- Publication type:
- Article
Works by García-Quintanilla, Laura
Results: 13
1
2
Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 2, p. 157, doi. 10.3390/ph17020157
- By:
- Publication type:
- Article
3
Clinical Effectiveness, Safety, and Compliance of Two Compounded Formulations of Tacrolimus Eye Drops: An Open-Label, Sequential Prospective Study.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 18, p. 9847, doi. 10.3390/ijms25189847
- By:
- Publication type:
- Article
4
Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review.
- Published in:
- 2022
- By:
- Publication type:
- Literature Review
5
The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration.
- Published in:
- Pharmaceutics, 2024, v. 16, n. 1, p. 105, doi. 10.3390/pharmaceutics16010105
- By:
- Publication type:
- Article
6
Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 11, p. 2615, doi. 10.3390/pharmaceutics15112615
- By:
- Publication type:
- Article
7
Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 10, p. N.PAG, doi. 10.3390/pharmaceutics14102194
- By:
- Publication type:
- Article
8
Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 3, p. 342, doi. 10.3390/pharmaceutics13030342
- By:
- Publication type:
- Article
9
Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration.
- Published in:
- Pharmaceutics, 2019, v. 11, n. 8, p. 365, doi. 10.3390/pharmaceutics11080365
- By:
- Publication type:
- Article
10
Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy.
- Published in:
- Farmacia Hospitalaria (1130-6343), 2024, v. 48, n. 1, p. T16, doi. 10.1016/j.farma.2023.09.009
- By:
- Publication type:
- Article
11
Farmacocinética de eculizumab en pacientes adultos y pediátricos con síndrome hemolítico urémico atípico y glomerulopatía C3.
- Published in:
- Farmacia Hospitalaria (1130-6343), 2024, v. 48, n. 1, p. 16, doi. 10.1016/j.farma.2023.07.009
- By:
- Publication type:
- Article
12
Correction: A Review of Population Pharmacokinetic Analyses of Linezolid.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
13
A Review of Population Pharmacokinetic Analyses of Linezolid.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 6, p. 789, doi. 10.1007/s40262-022-01125-2
- By:
- Publication type:
- Article